.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,674,471

« Back to Dashboard

Details for Patent: 5,674,471

Title: Aerosol formulations containing P134a and salbutamol
Abstract:The invention relates to a pharmaceutical aerosol formulation consisting essentially of particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% surfactant based upon the weight of medicament, particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.
Inventor(s): Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Filing Date:May 19, 1995
Application Number:08/444,725
Claims:1. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% surfactant based upon the weight of medicament, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

2. A formulation as claimed in claim 1 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

3. A formulation as claimed in claim 1 which has a respirable fraction of 20% or more by weight of particulate medicament.

4. A formulation as claimed in claim 1 wherein the salbutamol is in the form of its sulphate salt.

5. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is in the form of a physiologically acceptable salt and when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.0866%.

6. A formulation as claimed in claim 5 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

7. A formulation as claimed in claim 5 which has a respirable fraction of 20% or more by weight of particulate medicament.

8. A formulation as claimed in claim 5 wherein the salbutamol is in the form of its sulphate salt.

9. A pharmaceutical aerosol formulation consisting of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethene as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

10. A formulation as claimed in claim 9 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

11. A formulation as claimed in claim 9 which has a respirable fraction of 20% or more by weight of particulate medicament.

12. A formulation as claimed in claim 9 wherein the salbutamol is in the form of its sulphate salt.

13. A pharmaceutical aerosol formulation consisting essentially of the particulate medicaments salbutamol and beclomethasone dipropionate, or physiologically acceptable salts or solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of particulate medicament, the particulate medicaments being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

14. A formulation as claimed in claim 13 wherein the salbutamol is in the form of its sulphate salt.

15. A formulation as claimed in claim 13 which formulation is free of surfactant.

16. A formulation as claimed in claim 13 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

17. A pharmaceutical aerosol formulation consisting of the particulate medicaments salbutamol and beclomethasone dipropionate, or physiologically acceptable salts or solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

18. A formulation as claimed in claim 17 wherein the salbutamol is in the form of its sulphate salt.

19. A formulation as claimed in claim 17 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

20. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate there is present in an amount of less than 0.866% w/w based on the total weight of the formulation, with the proviso that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt.

21. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.594% w/w based on the total weight of the formulation, with the proviso that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt.

22. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.264% w/w based on the total weight of the formulation.

23. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.174% w/w based on the total weight of the formulation.

24. A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, which formulation is free of surfactant, and wherein the weight ratio of salbutamol or a pharmaceutically acceptable or solvate thereof to propellant is less than 0.05:18.

25. A formulation as claimed in claim 20 wherein the salbutamol is in the form of its sulphate salt.

26. A formulation as claimed in claim 21 wherein the salbutamol is in the form of its sulphate salt.

27. A formulation as claimed in claim 22 wherein the salbutamol is in the form of its sulphate salt.

28. A formulation as claimed in claim 23 wherein the salbutamol is in the form of its sulphate salt.

29. A formulation as claimed in claim 24, wherein the salbutamol is in the form of its sulphate salt.

30. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 1.

31. A method as claimed in claim 30 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

32. A method as claimed in claim 30 wherein the formulation has a respirable fraction of 20% or more by weight of particulate medicament.

33. A method as claimed in claim 30 wherein the salbutamol is in the form of its sulphate salt.

34. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 5.

35. A method as claimed in claim 34 wherein the salbutamol is in the form of its sulphate salt.

36. A method as claimed in claim 34 wherein the particulate medicament is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation.

37. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 9.

38. A method as claimed in claim 37 wherein the particulate medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

39. A method as claimed in claim 37 wherein the formulation has a respirable fraction of 20% or more by weight of particulate medicament.

40. A method as claimed in claim 37 wherein the salbutamol is in the form of its sulphate salt.

41. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 13.

42. A method as claimed in claim 41 wherein the formulation has a respirable fraction of 20% or more by weight of particulate medicament.

43. A method as claimed in claim 41 wherein the salbutamol is in the form of its sulphate salt.

44. A method as claimed in claim 41 which formulation is free of surfactant.

45. A method as claimed in claim 41 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

46. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 17.

47. A method as claimed in claim 46 wherein the formulation has a respirable fraction of 20% or more by weight of particulate medicament.

48. A method as claimed in claim 46 wherein the salbutamol is in the form of its sulphate salt.

49. A method as claimed in claim 46 wherein the particulate medicaments are present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.

50. A pharmaceutical aerosol formulation consisting of a particulate medicament which is salbutamol sulphate and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

51. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation of claim 50.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc